在第二阶段肥胖症治疗试验中体重下降15%, 目标是到2030年达到100B美元市场。 Viking Therapeutics reports 15% weight loss in phase 2 obesity treatment trials, targeting $100B market by 2030.

VKTX(VKTX)专门开发使用双重GIP/GLP-1受体激动剂的肥胖治疗方法,有希望的第二阶段结果显示体重减幅高达15%。 Viking Therapeutics (VKTX) specializes in developing obesity treatments using dual GIP/GLP-1 receptor agonists, with promising phase 2 results showing up to 15% weight loss. 肥胖药物市场正在迅速扩大,预计到2030年将达到1 000亿美元。 The obesity drug market is rapidly expanding, projected to reach $100 billion by 2030. Viking 拥有超过 9 亿美元的强大现金储备，并且还在探索 NASH 和 X-ALD 的治疗方法。 Viking has a strong cash reserve of over $900 million and is also exploring treatments for NASH and X-ALD. 虽然其股票显示出波动性,但分析家认为其他投资选择可能更有利。 While its stock has shown volatility, analysts suggest other investment options may be more favorable.